Matthew Scott Harris - 31 Jul 2025 Form 4 Insider Report for Altimmune, Inc. (ALT)

Reporting relationship: Chief Medical Officer
Issuer ticker: ALT
Reported as of: 31 Jul 2025
Net transaction value: +$6,337
SEC form: 4
Accepted by SEC: 04 Aug 2025, 16:05:50 UTC
Prior SEC filing: 11 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Greg Weaver, as Attorney-in-Fact

Key filing fact

Matthew Scott Harris filed Form 4 for Altimmune, Inc. (ALT) on 04 Aug 2025.

Key facts

This page summarizes Matthew Scott Harris's Form 4 filing for Altimmune, Inc. (ALT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Aug 2025, 16:05.

Change

Previous filing in this sequence was filed on 11 Mar 2025.
Current net transaction value: +$6,337.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001787762 Primary reporting owner

Harris Matthew Scott

Relationship: Chief Medical Officer
Address: C/O ALTIMMUNE, INC.,, 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG
Signature: /s/ Greg Weaver, as Attorney-in-Fact
Signature date: 04 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALT transaction

Common Stock, par value $0.0001

Award

Transaction value: $6,337
Shares: +2,018
Change %: +14%
Price: $3.14
Shares after: 16,087
Date: 31 Jul 2025
Ownership: Direct
Footnotes: F1, F2

ALT holding

Common Stock, par value $0.0001

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 67,787
Date: 31 Jul 2025
Ownership: By Matthew Scott Harris Trust

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares were purchased due to participation of the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2025 through July 31, 2025.

Footnote F2

In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock.